SG11201913968VA - Proteins binding nkg2d, cd16 and a tumor-associated antigen - Google Patents
Proteins binding nkg2d, cd16 and a tumor-associated antigenInfo
- Publication number
- SG11201913968VA SG11201913968VA SG11201913968VA SG11201913968VA SG11201913968VA SG 11201913968V A SG11201913968V A SG 11201913968VA SG 11201913968V A SG11201913968V A SG 11201913968VA SG 11201913968V A SG11201913968V A SG 11201913968VA SG 11201913968V A SG11201913968V A SG 11201913968VA
- Authority
- SG
- Singapore
- Prior art keywords
- tumor
- associated antigen
- proteins binding
- binding nkg2d
- nkg2d
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549201P | 2017-08-23 | 2017-08-23 | |
| US201762558514P | 2017-09-14 | 2017-09-14 | |
| US201762558511P | 2017-09-14 | 2017-09-14 | |
| US201762558509P | 2017-09-14 | 2017-09-14 | |
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US201762566828P | 2017-10-02 | 2017-10-02 | |
| US201762581357P | 2017-11-03 | 2017-11-03 | |
| US201762608384P | 2017-12-20 | 2017-12-20 | |
| PCT/US2018/047714 WO2019040727A1 (en) | 2017-08-23 | 2018-08-23 | BINDING PROTEINS FOR NKG2D, CD16 AND ANTIGEN ASSOCIATED WITH A TUMOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201913968VA true SG11201913968VA (en) | 2020-01-30 |
Family
ID=65439284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201913968VA SG11201913968VA (en) | 2017-08-23 | 2018-08-23 | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200231679A1 (enExample) |
| EP (1) | EP3672993A4 (enExample) |
| JP (2) | JP2020531525A (enExample) |
| KR (1) | KR20200038530A (enExample) |
| CN (1) | CN111315778A (enExample) |
| AU (1) | AU2018322178A1 (enExample) |
| BR (1) | BR112020003654A2 (enExample) |
| CA (1) | CA3072919A1 (enExample) |
| IL (2) | IL311488A (enExample) |
| MX (1) | MX2020002036A (enExample) |
| RU (1) | RU2020111554A (enExample) |
| SG (1) | SG11201913968VA (enExample) |
| WO (1) | WO2019040727A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3579848B1 (en) | 2017-02-08 | 2024-10-30 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| SG11202101298XA (en) | 2018-08-08 | 2021-03-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| US20240117054A1 (en) * | 2019-10-15 | 2024-04-11 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and flt3 |
| US20230073946A1 (en) * | 2020-01-20 | 2023-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Affinity peptide conjugated with antioxidant for protection of proteins from oxidation |
| AR122018A1 (es) * | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y clec12a |
| CN114437214B (zh) * | 2020-11-03 | 2023-06-02 | 南京北恒生物科技有限公司 | 靶向lir1的抗体及其用途 |
| US20240034795A1 (en) * | 2020-12-31 | 2024-02-01 | Innovent Biologics (Suzhou) Co., Ltd. | Protein containing heterodimer antibody fc, and preparation method therefor |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| WO2025166138A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + tslp targeting antibodies and uses thereof |
| WO2025166146A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + ox40 targeting antibodies and uses thereof |
| CN118812708B (zh) * | 2024-06-28 | 2025-04-04 | 北京普利米特生物科技有限公司 | 抗il-33抗体或其抗原结合片段及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038339A1 (en) * | 2000-03-24 | 2004-02-26 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| MX380352B (es) * | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| KR101615935B1 (ko) * | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2014145806A2 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| ES3033286T3 (en) * | 2014-03-05 | 2025-08-01 | Autolus Ltd | Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2 |
| AU2016206707A1 (en) * | 2015-01-14 | 2017-08-10 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| EP3258967A4 (en) * | 2015-02-20 | 2018-10-03 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| DK3313876T3 (da) * | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| WO2017081190A1 (en) * | 2015-11-13 | 2017-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| WO2017124002A1 (en) * | 2016-01-13 | 2017-07-20 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| WO2018148447A1 (en) * | 2017-02-08 | 2018-08-16 | Adimab, Llc | Antibody heavy chain variable domains targeting the nkg2d receptor |
| SG11201907253VA (en) * | 2017-02-10 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding bcma, nkg2d and cd16 |
-
2018
- 2018-08-23 SG SG11201913968VA patent/SG11201913968VA/en unknown
- 2018-08-23 IL IL311488A patent/IL311488A/en unknown
- 2018-08-23 AU AU2018322178A patent/AU2018322178A1/en not_active Abandoned
- 2018-08-23 CA CA3072919A patent/CA3072919A1/en active Pending
- 2018-08-23 JP JP2020511319A patent/JP2020531525A/ja not_active Ceased
- 2018-08-23 EP EP18848423.2A patent/EP3672993A4/en not_active Withdrawn
- 2018-08-23 KR KR1020207007908A patent/KR20200038530A/ko not_active Ceased
- 2018-08-23 US US16/639,150 patent/US20200231679A1/en not_active Abandoned
- 2018-08-23 BR BR112020003654-4A patent/BR112020003654A2/pt not_active IP Right Cessation
- 2018-08-23 MX MX2020002036A patent/MX2020002036A/es unknown
- 2018-08-23 RU RU2020111554A patent/RU2020111554A/ru unknown
- 2018-08-23 WO PCT/US2018/047714 patent/WO2019040727A1/en not_active Ceased
- 2018-08-23 CN CN201880054953.2A patent/CN111315778A/zh active Pending
-
2020
- 2020-02-16 IL IL272706A patent/IL272706A/en unknown
-
2023
- 2023-02-24 JP JP2023027219A patent/JP2023062184A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111315778A (zh) | 2020-06-19 |
| WO2019040727A1 (en) | 2019-02-28 |
| IL272706A (en) | 2020-04-30 |
| US20200231679A1 (en) | 2020-07-23 |
| RU2020111554A3 (enExample) | 2022-01-19 |
| RU2020111554A (ru) | 2021-09-23 |
| JP2020531525A (ja) | 2020-11-05 |
| EP3672993A4 (en) | 2021-10-27 |
| EP3672993A1 (en) | 2020-07-01 |
| IL311488A (en) | 2024-05-01 |
| CA3072919A1 (en) | 2019-02-28 |
| JP2023062184A (ja) | 2023-05-02 |
| AU2018322178A1 (en) | 2020-02-20 |
| MX2020002036A (es) | 2020-03-24 |
| KR20200038530A (ko) | 2020-04-13 |
| BR112020003654A2 (pt) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281323A (en) | Proteins that bind D2NKG, 16CD, and tumor-associated antigen | |
| IL272706A (en) | Proteins that bind D2NKG, 16CD, and tumor-associated antigen | |
| SG11202101294RA (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
| IL270801A (en) | NKG2D, CD16 and tumor-associated antigen binding protein | |
| IL268755B2 (en) | Proteins that bind her2, nkg2d, and cd16 | |
| SG11202101298XA (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
| IL270803A (en) | A protein binding nkg2d, cd16 and a tumor-associated antigen | |
| IL268790A (en) | CD33, NKG2D and CD16 binding proteins | |
| IL270794A (en) | NKG2D binding protein, CD16 and ROR1 or ROR2 | |
| IL280656A (en) | Multispecific binding proteins that bind HER2, NKG2D, and CD16 and methods of use | |
| IL268567A (en) | BCMA, NKG2D and CD16 binding proteins | |
| IL268574A (en) | proteins that bind psma, nkg2d, and cd16 | |
| IL268766A (en) | Proteins that bind NKG2D, CD123, and CD16 | |
| SG11202000632QA (en) | Proteins binding nkg2d, cd16 and flt3 | |
| ZA202003641B (en) | Antibodies binding ctla-4 and uses thereof | |
| IL268768A (en) | Proteins binding gd2, nkg2d and cd16 | |
| HK40027627A (en) | A protein binding nkg2d, cd16 and a tumor-associated antigen | |
| HK40027626A (en) | A protein binding nkg2d, cd16 and a tumor-associated antigen | |
| HK40054606A (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
| ZA201905273B (en) | Proteins binding psma, nkg2d and cd16 | |
| HK40019734A (en) | Proteins binding cd123, nkg2d and cd16 | |
| HK40019178A (en) | Proteins binding psma, nkg2d and cd16 | |
| HK40030226A (en) | Proteins binding nkg2d, cd16 and flt3 | |
| HK40014039A (en) | Proteins binding cd33, nkg2d and cd16 | |
| HK40014030A (en) | Proteins binding bcma, nkg2d and cd16 |